Dormire

Quick links to important sections

Dormire

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dormire

Quick Facts

Property Description
Active ingredient Midazolam (usually as Midazolam hydrochloride)
Form Solution for injection, Oral syrup, Nasal/Buccal solution
Pharmacological class Benzodiazepine (Central Nervous System Depressant)
Common use Sedation and anxiety relief (anxiolysis)
Origin Synthetic compound

What Type of Medication is Dormire?

The medicinal product Dormire is the trade name for the powerful, synthetic active substance Midazolam, which is chemically defined as an Imidazobenzodiazepine. It is classified as a short-acting Central Nervous System (CNS) depressant and belongs to the broader Benzodiazepine pharmacological class. Midazolam is a single-component product valued for its rapid action and short duration.

This specific type of benzodiazepine is uniquely formulated as the water-soluble salt, Midazolam hydrochloride, which facilitates rapid administration and absorption. This crucial chemical characteristic differentiates it from long-acting analogues and is key to its positioning for acute, short-duration clinical needs.

What is the General Purpose of Midazolam?

The general purpose of a medicine containing Midazolam is to act as a hypnotic-sedative agent, primarily aimed at providing fast and reliable anxiety relief (anxiolysis) and effective sedation. The active substance has an established role in quickly quieting the central nervous system. This fast-acting, calming effect makes it clinically recognized for inducing a state of deep tranquility before necessary procedures.

A core functional property is the capacity of Midazolam to cause anterograde amnesia, meaning it limits the brain’s ability to form new memories during the period of drug activity. To ensure flexibility, Midazolam is prepared in several core forms—including an aqueous solution for injection, oral syrup, and specialized nasal and buccal solutions—all supporting immediate action.

Regulatory References

  1. NIH Midazolam StatPearls Article
  2. Midazolam - StatPearls - NCBI Bookshelf
  3. EMA Buccolam (Midazolam) EPAR

What side effects are possible with Dormire?

Possible side effects and safety information

The safety profile for Midazolam (Dormire) is primarily structured around the risk of Cardiorespiratory Adverse Reactions, which are documented in official regulatory labeling. This category includes common events like decreased respiratory rate and apnea, as well as the serious risk of respiratory arrest and cardiac arrest, which have resulted in severe outcomes.

Documented Adverse Reactions

Adverse effects are officially classified by the physiological system affected. Nervous System and Psychiatric Disorders are common domains, encompassing expected pharmacological effects such as sedation, somnolence, and anterograde amnesia (impaired short-term recall). Less common effects include paradoxical reactions like agitation, hostility, and involuntary movements. Vascular and Cardiac effects primarily involve changes in blood pressure, notably hypotension.

Classification Common Examples (as per regulatory data)
Respiratory Decreased respiratory rate, apnea, hypoventilation
CNS Sedation, somnolence, anterograde amnesia, dizziness
Gastrointestinal Nausea, vomiting

Serious Safety Considerations

The most significant, life-threatening concerns documented in prescribing information are the potential for respiratory arrest and cardiac arrest. Furthermore, the regulatory safety profile states that physical dependence and a withdrawal syndrome may occur following prolonged use of several days to weeks.

Specific safety statements are documented for vulnerable populations: Older adults face a greater danger of hypoventilation and apnea. Patients with pre-existing conditions like hepatic impairment may experience stronger and prolonged effects, and use in neonates can lead to profound respiratory effects. Concomitant use with opioids or other Central Nervous System depressants is documented as significantly increasing the risk of profound sedation, coma, and death.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Dormire (Midazolam) by detailing the expected manifestations and the required emergency actions.

Overdose resulting from a supra-therapeutic dose is formally documented to present as profound sedation, excessive sleepiness, and lack of coordination, progressing to more severe signs such as respiratory depression, hypoventilation, and hypotension.

Documented Severe Outcomes and Required Actions

Regulator-listed severe outcomes include respiratory arrest, cardiac arrest, death, and the potential for permanent neurologic injury. The official labeling mandates that patients exhibiting severe symptoms, particularly apnea (breathing stops), must seek immediate medical attention or get emergency help right away.

Treatment is defined as symptomatic and supportive, requiring the maintenance of a patent airway and access to resuscitative drugs and equipment for assisted breathing. A specific reversal agent, flumazenil, is documented for the complete or partial antagonism of the central sedative effects in cases of overdose.

Population-Specific Overdose Considerations

The risk of severe consequences, particularly hypoventilation and apnea, is noted as greater in elderly patients (over 60 years) and in patients with underlying conditions such as chronic renal failure or impaired hepatic function. These populations require continuous monitoring of cardiorespiratory function during management, as specified in regulatory information.

Therapeutic Uses of Dormire

What Dormire Treats: Main Uses and Benefits

The primary role of Dormire (Midazolam) is in providing short-term, supportive symptom management across several critical and procedural contexts. The medication is commonly used to help ease symptoms related to heightened physiological activity and significant patient distress.

Managing Symptoms and Clinical Contexts

Dormire is generally applied in contexts involving heightened systemic burden, supporting patients during episodes of increased distress. It is commonly used to help with procedural sedation (calming anxiety for procedures like endoscopy), emergency symptom management (addressing severe, prolonged convulsions), and supportive sedation in critical care for intubated patients.

This medication assists with maintaining functional stability by helping ease the impact of restlessness and supports patient comfort during difficult episodes.

“The primary goal is to safely manage acute symptom flares, such as intense anxiety or severe seizures, by providing quick, effective symptomatic relief.”

Quick Fact: Symptom Management Summary

Symptom Domain Symptom Cluster Managed Symptomatic Support
Procedural Anxiety, apprehension, tension Assists with amnesia (memory loss)
Neurological Prolonged, severe convulsions Supports managing symptoms of increased neurological activity
Critical Care Agitation, restlessness, distress Contributes to easing the overall symptom load

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for Dormire (Midazolam) is strictly governed by regulatory documentation, which defines populations who must not use the medicine and those who require significant caution.

Contraindicated Populations

The medicine is formally prohibited for patients with a known hypersensitivity to midazolam or other benzodiazepines. It must not be used in individuals with severe respiratory insufficiency or acute narrow-angle glaucoma, due to the risk of respiratory depression and other complications.

Conditional Eligibility and Restrictions

Population Group Regulatory Restriction / Status
Older Adults (Geriatric) Require a significantly lower initial dose due to increased sensitivity to central nervous system (CNS) effects.
Severe Organ Impairment Patients with severe hepatic or renal impairment must be administered the medicine with caution due to the risk of delayed elimination.
Pregnancy/Lactation Use is not recommended during the first trimester. Use in late pregnancy is associated with documented risk of neonatal sedation and withdrawal. Temporary cessation of breastfeeding is recommended after administration.
Pediatric (Under 6 months) Use for conscious sedation is limited/not established due to heightened vulnerability to airway obstruction.

The official label states that eligibility is restricted in patients with severe, chronic respiratory diseases (like COPD) due to increased sensitivity to the CNS depressant effect. This conditional eligibility requires careful monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dormire (Midazolam) primarily through its metabolism by the CYP3A4 enzyme and its action as a Central Nervous System (CNS) depressant.

Contraindicated Combinations and Restrictions

Co-administration with opioid analgesics and other CNS depressants carries the highest regulatory restriction due to the risk of profound sedation, respiratory depression, coma, and death. Use for conscious sedation is also strictly restricted in patients with severe respiratory failure. Midazolam is contraindicated in patients with acute narrow-angle glaucoma.

Pharmacokinetic and Pharmacodynamic Effects

Interaction Type Interacting Substances Regulatory Outcome
Pharmacodynamic Opioid Analgesics, Alcohol, Other Sedatives Potentiation of CNS depressant effects
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., Azole Antifungals, Macrolides) Decreased plasma clearance, prolonged effects
Pharmacokinetic Strong CYP3A4 Inducers (e.g., Rifampicin, Phenytoin) Decreased plasma concentration, reduced effect

Specific dietary substances, such as Grapefruit Juice, are documented to increase oral Midazolam exposure. Special cautions apply to elderly or debilitated patients and those with decreased pulmonary reserve, as they face a greater risk of adverse cardiorespiratory reactions when Midazolam is co-administered with other CNS depressants.

Mechanism of Action

Modulating CNS Inhibition via GABA A Receptors

Midazolam acts as a Positive Allosteric Modulator that binds to the benzodiazepine site on the GABA A receptor complex, the brain's main inhibitory ion channel. This mechanism enhances the effect of the inhibitory neurotransmitter GABA, causing a greater influx of chloride ions ( Cl^-) into the neurons, which leads to neuronal hyperpolarization and a significant decrease in nerve cell excitability.


Dampening Arousal and Emotional Regulation Pathways

The widespread reduction in neuronal excitability directly affects systems responsible for alertness and emotional control, specifically the Reticular Activating System (RAS) and the Limbic System. By enhancing inhibition within these centers, the mechanism suppresses arousal and decreases emotional response, contributing to the physiological states of reduced arousal and decreased emotional response. This widespread decrease in neuronal excitability produces a physiological state characterized by reduced systemic responsiveness to excitatory stimuli.


Mechanism of Transient Memory Disruption

A specific consequence of the intense inhibitory action is its effect on brain regions involved in memory formation, such as the hippocampus. The mechanism prevents the cellular processes needed to consolidate new experiences into memory, resulting in anterograde amnesia—the inability to form new memories during the period of drug activity. This disruption of memory encoding within the hippocampus modulates activity in the cognitive-behavioral pathways, contributing a distinct element to the compound’s overall physiological profile.

Dosage and Administration Information

How Dormire is Used

The administration of Dormire (Midazolam) follows established parameters that define the utilized routes, precise dosing, and procedural conditions. The medication is utilized through several routes, including Intravenous (IV) and Intramuscular (IM) injection, as well as non-parenteral Oral, Intranasal (IN), and Buccal methods, providing flexibility for different acute needs.

Dosing is highly individualized and initiated at the lowest effective amount. For IV procedural sedation, the initial dose is typically le 2.5 mg and is administered slowly over a period of ge 2 minutes. Subsequent doses are added incrementally, with a waiting period of ge 2 minutes before any further administration to allow for full evaluation.

Use Patterns and Adjustments

Specific population-based instructions involve a dose reduction for older adults (age ge 60) and debilitated patients, where the initial IV dose may be reduced to le 1 mg and titrated more slowly. Pediatric dosing is weight-based (mg/kg) across utilized routes. The use of Dormire is intended for short-term or intermittent administration for acute events. In cases where the drug has been administered via a continuous IV infusion over an extended period, a gradual taper of the dose is employed upon discontinuation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dormire

Evidence for Use in Conscious Sedation for Procedures

Dormire (Midazolam) was studied for exploring outcomes related to anxiety relief and sedation before and during diagnostic or therapeutic procedures. Research examined different routes of administration (intravenous, oral, nasal) compared to placebo or other sedating medicines. Studies focused on the level of sedation achieved, measurements of anxiety relief (anxiolysis), and the presence of amnesia. Findings describe patterns observed in studies where measurements of sedation and amnesia were recorded for patients receiving Midazolam compared to controls. Comparative evidence is lacking for some direct comparisons against every alternative sedative. Follow-up durations were limited, focusing on immediate recovery.


Evidence for Use in Managing Acute, Severe Seizures

Dormire was evaluated in research exploring short-term symptom changes associated with acute, prolonged convulsive seizures. Studies compared non-intravenous Midazolam (buccal, nasal, or intramuscular) against other medicines evaluated in these acute settings. Research examined outcomes like the total seizure cessation rate (frequency of seizure termination) and the time to seizure cessation. Data show patterns related to rapid action. However, long-term effects are not fully established regarding neurological function or seizure recurrence weeks later, as research explored short-term symptom changes only.


What Research Remains Uncertain or Limited

While research contributes to the broader evidence landscape, certainty remains low in specific areas. Comparative evidence is lacking in some areas, making it difficult to fully contextualize Midazolam’s performance against every possible alternative sedative across all measured outcomes. Furthermore, the potential for tolerance to develop with prolonged, continuous use in the critical care setting was associated with difficulties in weaning the patient off the medicine. Studies confirm that research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Intranasal midazolam versus intravenous/rectal benzodiazepines for acute seizure control in children: A systematic review and meta-analysis
  2. Midazolam, Etomidate, Propofol, Fentanyl, Ketamine, and Propofol/Ketamine for Procedural Sedation and Analgesia Among Adults in the Emergency Departments: A Systematic Review
  3. Midazolam infusions for therapeutic management of pediatric refractory status epilepticus: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Dormire (FAQ)

Q: Why do some people compare Dormire to other similar medicines?

Regulatory evidence indicates that Dormire (Midazolam) is frequently compared to other sedative medicines. This comparison is primarily due to its unique pharmacological profile, which includes a notably rapid onset, a shorter duration of action, and the ability to cause anterograde amnesia (impaired short-term memory). These properties support its positioning for use in medical procedures requiring short, controlled periods of sedation.

Q: Is Dormire considered a first-line treatment option?

Official clinical guidance suggests Dormire (Midazolam) is often considered the benzodiazepine of choice for procedures requiring short-term conscious sedation. However, for long-term sedation in critical care settings, official recommendations state that other, non-benzodiazepine medicines are generally preferred.

Q: Can Dormire affect your mood or energy levels during the day?

According to official product information, Dormire can affect central nervous system function. Documented side effects include drowsiness and somnolence, which can be associated with a 'hangover' effect persisting into the next day. Rarer effects noted are paradoxical reactions such as agitation, restlessness, and mood swings.

Q: How long do the common side effects of Dormire typically last?

Due to the medication's short duration of action, most common side effects like drowsiness and impaired coordination are usually short-lived. Official sources indicate these effects may persist for at least 24 hours or up to 1 or 2 days following administration.

Q: What are the signs of a serious allergic reaction to Dormire?

The official safety information notes that known hypersensitivity to Dormire is a contraindication. Signs of a serious allergic reaction that have been documented in adverse reaction reports include skin rash, hives, and itching. Swelling of the face, lips, tongue, or throat are also noted symptoms reported to require immediate medical evaluation.

Q: Are there any known interactions between Dormire and over-the-counter pain relievers?

Regulatory documents state that Dormire should be used with caution when taken with any other medication that acts as a Central Nervous System (CNS) depressant. While specific OTC pain relievers are not universally contraindicated, combining Dormire with other CNS depressants, including certain allergy medicines or some OTCs, may increase the risk of over-sedation.

Q: Can Dormire be taken with prescription medicines for blood pressure or heart conditions?

Official warnings state that Dormire can cause hypotension, which is a decrease in mean arterial pressure, and may affect cardiac output. Therefore, patients with pre-existing heart conditions or those taking blood pressure medications require significant caution. Regulatory guidance requires close monitoring of patients in these populations.

Q: Is it safe to take Dormire with common multivitamins or dietary supplements?

Regulatory guidance states that a healthcare provider should be informed of all medications, vitamins, and herbal products before taking Dormire. This is because certain dietary supplements or herbal products, such as St. John's Wort, are known to interact with the liver enzymes that process Dormire. These interactions could potentially affect how long the medication stays in the body.

Q: How quickly should I expect Dormire to start having an effect?

Official clinical data describes the onset of Dormire's effects based on the route of administration. Following intravenous (IV) injection, sedation is typically achieved within 3 to 5 minutes. After intramuscular (IM) injection, the effects generally begin in about 15 minutes, reaching peak sedation between 30 and 60 minutes.

Q: What is the usual expected timeframe for the drug's effect to wear off?

Clinical pharmacology information states that the elimination half-life (the time it takes for half of the drug to be eliminated from the body) ranges from about 1.8 to 6.4 hours in healthy adults. The total duration of effect is generally short, which is consistent with its use in brief medical procedures.

Q: Is it common for people to not notice a difference right away with Dormire?

While the sedative effect is expected to be rapid, particularly after intravenous administration, the drug's intended action includes causing anterograde amnesia. This means a high percentage of patients may not remember the procedure or the period immediately following administration, even if the medication worked quickly to achieve the desired clinical state.

Q: What if someone has a history of substance dependence—can they take Dormire?

Official regulatory warnings state that Midazolam is associated with risks of misuse, abuse, and dependence. The label indicates that its use in patients with a history of substance abuse requires caution. Dependence and a withdrawal syndrome can also occur after prolonged use.

Q: Where can I find the official clinical trial results for Dormire?

Official summaries of the clinical trial data are typically found within the 'Clinical Studies' section of the FDA-approved prescribing information (the official label). Additional information and results may also be available in dedicated, government-run medical and scientific databases such as those managed by the National Institutes of Health (NIH).

Q: Is a generic version of Dormire currently available?

Official sources confirm that Midazolam is the active substance in Dormire. The generic version, Midazolam, is widely available from various manufacturers in multiple approved formulations. This availability applies to products approved by the FDA and other major regulatory bodies.

Q: What information should I look for on the official Dormire package insert?

Key sections of the regulatory documentation include the Boxed Warning, which describes severe cardiorespiratory risks, and the sections detailing Contraindications (who should not use it), Warnings and Precautions, and Drug Interactions.

Q: Does Dormire cause trouble sleeping as a side effect?

While Dormire is used for sedation, official regulatory data lists 'trouble sleeping' (insomnia or sleep disturbances) as a possible, though less common, adverse reaction. This paradoxical reaction means the medicine can, in rare cases, have the opposite of its intended effect on sleep.

Q: What are the known components (active and inactive ingredients) of Dormire?

The medication's active component is Midazolam, specifically formulated as Midazolam hydrochloride. Inactive ingredients vary widely depending on whether the medication is an injection, oral syrup, or nasal spray. Official regulatory documents include specific warnings for some inactive ingredients, such as benzyl alcohol, which is present in certain injection formulations.

Q: Is Dormire approved for use in countries outside of the US, like in Europe or Canada?

Official regulatory bodies outside of the United States, such as the European Medicines Agency (EMA) and Health Canada, have approved and recognize the active substance Midazolam. This means it is an established medication used globally for its recognized indications, including sedation and the management of acute seizures.

Q: Are there any restrictions on driving or operating machinery while on Dormire?

Official regulatory information states that activities requiring full mental alertness, such as driving or operating machinery, are restricted for at least 24 hours after receiving Dormire, or until the drug's effects have completely worn off. This is due to the potential for impaired memory, thinking, and motor functions.

How should Dormire be stored and disposed of?

Storage Conditions and Security

Dormire (Midazolam) must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The official label permits temporary temperature excursions up to 30 C (86 F). The oral syrup and specific solutions should be protected from light. As a controlled substance, the medication must be kept in a safe and secure location to prevent unauthorized access or theft.

Handling and Stability

The medicine must be kept out of the sight and reach of children. Single-dose injection containers require that the unused portion remaining after a dose is drawn must be immediately discarded. If the injection is diluted for infusion, the final solution is typically stable for up to 24 hours at room temperature.

Disposal Instructions

Official disposal protocols recommend utilizing a drug take-back program or authorized collection site. If a take-back option is unavailable, the unused medication should be mixed with an undesirable substance (such as used coffee grounds or kitty litter), placed into a sealed container, and then thrown into the household trash. The medication must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dormire found in:

A-Z Index: